NCT02546661 2025-12-29
BISCAY
AstraZeneca
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT00648648 2023-09-21
MK-1775-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01047007 2023-09-21
A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02482311 2023-07-03
Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02610075 2023-07-03
Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
AstraZeneca
Phase 1 Completed
NCT04959266 2022-09-16
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
AstraZeneca
Phase 1 Terminated
NCT05008913 2022-09-06
ADME
AstraZeneca
Phase 1 Terminated
NCT04949425 2022-09-02
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Terminated
NCT04462952 2022-07-25
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02511795 2019-11-07
AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
AstraZeneca
Phase 1 Completed
NCT02341456 2019-03-25
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
AstraZeneca
Phase 1 Completed